ABSTRACT
BACKGROUND: Coronavirus disease 2019 makes patients more susceptible to superinfection of fungal disease as a consequence of immunological system impairment. Mucormycosis is a fungal infection that is rare but has a high mortality rate and mostly affects patients with poorly controlled diabetes mellitus or those receiving corticosteroids. CASE PRESENTATION: Here, we present a case of post-coronavirus disease 2019 mucormycosis in a 37-year-old Persian male presenting with multiple periodontal abscess with purulent discharge and necrosis of maxillary bone (without oroantral communication). Surgical debridement following antifungal therapy was the treatment of choice. CONCLUSION: Early diagnosis and immediate referral are the cornerstone of comprehensive treatment.
Subject(s)
Mucormycosis , Periodontal Abscess , Post-Acute COVID-19 Syndrome , Adult , Humans , Male , Mucormycosis/diagnosis , Mucormycosis/etiology , Mucormycosis/therapy , Periodontal Abscess/diagnosis , Periodontal Abscess/etiology , Periodontal Abscess/therapy , Maxilla/microbiology , Maxilla/surgery , Post-Acute COVID-19 Syndrome/complications , Post-Acute COVID-19 Syndrome/diagnosis , Debridement , Necrosis , Antifungal Agents/therapeutic useABSTRACT
It is important to increase the awareness and knowledge of head and neck surgeons about the recent surge of craniofacial mucormycosis in COVID-19 patients because early diagnosis and appropriate treatment are essential to improve the outcomes. Here, we describe clinical features, treatment protocols, and outcomes of treatment in eight patients with COVID-19-associated mucormycosis in the maxilla. Consistent with the findings of previous studies, our experience in the management of these eight patients shows that early administration of amphotericin B and prompt aggressive surgery are essential for optimal control of the disease.